Synopsys v. Real Intent: Six EDA Patents, Dismissed in 5 Days
Synopsys filed suit against Real Intent in Delaware federal court, asserting six patents covering electronic design automation clock domain crossing verification against Real Intent’s Least Meridian CDC product. The action was voluntarily dismissed without prejudice under Rule 41(a)(1)(A) just five days after filing — one of the shortest-lived patent disputes in the Delaware District Court.
Six-patent EDA dispute extinguished before Real Intent could respond
On 21 March 2025, Synopsys, Inc. filed a patent infringement complaint against Real Intent, Inc. in the U.S. District Court for the District of Delaware before Judge Richard G. Andrews. The complaint asserted six U.S. patents — US9529948B2, US8359560B2, US8650513B2, US9792394B2, US10289773B2, and US8607173B2 — all directed at electronic design automation technology, specifically clock domain crossing (CDC) verification. The accused product was Real Intent’s Least Meridian CDC tool, a direct competitor to Synopsys’s own CDC verification offerings.
On 26 March 2025 — five days after filing — Synopsys voluntarily dismissed the action without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). This mechanism, available before a defendant has served an answer or motion for summary judgment, requires no court order and leaves no judgment on the merits. The dismissal without prejudice is legally significant: Synopsys preserves its right to refile the same claims against Real Intent in any competent jurisdiction, subject to applicable statutes of limitations.
The five-day lifespan of this case is exceptional even by the standards of early voluntary dismissals. No defendant counsel of record was entered and no substantive court activity appears on the docket, suggesting the dismissal may reflect a rapid pre-litigation settlement, a strategic recalibration of venue or claim scope, or an administrative correction. The public record does not disclose any agreed terms, financial consideration, or licensing arrangement, leaving the commercial resolution — if any — unknown.
Filing to Dismissed without Prejudice in 5 days
Case closed in 5 days — unusually rapid resolution for a multi-patent EDA infringement action
Voluntarily dismissed: what Rule 41 without prejudice means for both parties
Rule 41(a)(1)(A): plaintiff’s unilateral exit before answer
Under Fed. R. Civ. P. 41(a)(1)(A)(i), a plaintiff may dismiss an action without a court order at any time before the defendant serves an answer or a motion for summary judgment. Synopsys invoked this right within five days of filing. The dismissal carries no preclusive effect — no judgment was entered, no claims were decided on the merits, and the litigation record is effectively reset.
No merits adjudicationWithout prejudice: the public record does not specify settlement
A dismissal without prejudice preserves the plaintiff’s right to refile. A dismissal with prejudice would have permanently barred Synopsys from reasserting the same claims. The Basis of Termination here is explicitly ‘without prejudice.’ However, the public docket is silent on whether any private settlement, licensing agreement, or other commercial consideration accompanied the dismissal — that distinction matters significantly for Real Intent’s future exposure.
Refiling right preservedNo answer filed — Real Intent faces residual litigation risk
Real Intent had not entered counsel or filed any responsive pleading before the dismissal. While this case is closed, Real Intent cannot treat the matter as fully resolved: the six asserted patents remain valid and enforceable, and Synopsys retains the option to refile. Real Intent’s Least Meridian CDC product remains a potential target unless a licensing or design-around arrangement has been reached privately.
Six patents still liveEDA CDC verification: Synopsys signals aggressive IP posture
The decision to assert six CDC-related patents simultaneously — then withdraw within five days — is consistent with pre-litigation pressure tactics or rapid out-of-court resolution. For EDA vendors operating in the CDC verification space, the case signals that Synopsys is willing to leverage its extensive CDC patent portfolio aggressively. Competitors offering overlapping functionality should treat this filing as a portfolio enforcement warning, regardless of its swift resolution.
EDA sector IP risk elevatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Synopsys, Inc. | Company | EDA software leader — holder of US9529948B2 and five CDC verification patentsSearch in Eureka ↗ |
| Defendant | Real Intent, Inc. | Company | Real Intent, Inc. — EDA vendor offering the Least Meridian CDC verification toolSearch in Eureka ↗ |
| Plaintiff counsel | Anne Shea Gaza | Attorney | Counsel for Synopsys, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Young Conaway Stargatt & Taylor, LLP | Law Firm | Representing Synopsys, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal was filed by Synopsys unilaterally under Rule 41(a)(1)(A)(i), before Real Intent had served any responsive pleading. The phrasing ‘without prejudice’ is legally precise: no claim was decided, no estoppel attaches, and the six asserted patents retain full enforceability. The swift exit — five days after filing — does not constitute a concession on the merits by either party. Real Intent receives no declaratory judgment of non-infringement and no covenant not to sue from the public record alone.
US9529948B2 and five further EDA CDC verification patents
The six patents asserted by Synopsys — US9529948B2, US8359560B2, US8650513B2, US9792394B2, US10289773B2, and US8607173B2 — collectively span a broad suite of electronic design automation (EDA) technologies directed at clock domain crossing (CDC) verification. CDC verification is a critical step in modern semiconductor design, ensuring that signals crossing between different clock domains in an integrated circuit are correctly handled to prevent metastability and functional failures. The patents’ application numbers suggest priority filings ranging across approximately 2010–2017, covering the evolution of CDC analysis from rule-based checking to more sophisticated formal and automated methods.
Synopsys is the dominant commercial force in EDA CDC verification, and this patent portfolio represents a meaningful defensive and offensive moat around its VC Formal and Synopsys CDC products. Real Intent’s Least Meridian CDC tool competes directly in this segment, making it a logical enforcement target. For any EDA vendor, semiconductor IP company, or chip design team deploying or developing CDC verification tooling, the breadth of this six-patent assertion — spanning structural analysis, formal methods, and automated CDC detection — means that freedom-to-operate clearance is non-trivial and should be revisited in light of this enforcement signal.
Should you run an FTO analysis against Synopsys’s six CDC patents?
Any engineering team developing or commercialising CDC verification tools, formal verification platforms, or automated EDA workflows for clock domain analysis should treat this enforcement action as a direct signal. Synopsys has demonstrated willingness to assert all six patents simultaneously against a direct competitor’s product. Even with this case dismissed without prejudice, the patents are live and the litigation risk has not been extinguished. R&D teams integrating CDC checking into EDA pipelines — whether for in-house design or commercial tool development — face non-trivial infringement exposure across the claim scope of these six patents.
PatSnap Eureka’s FTO Search Agent can map your CDC verification implementation against the independent and dependent claims of all six asserted patents, identify prior art that may inform invalidity arguments, and surface any continuation or divisional applications that could extend Synopsys’s enforcement window. Eureka’s portfolio analytics also allow you to monitor Synopsys’s prosecution activity in real time — giving you advance warning of new claims that may broaden or narrow the scope of existing patents before they issue.
Run a freedom-to-operate analysis on US9529948B2 to assess your product’s exposure
Run FTO in Eureka →Similar EDA patent infringement cases in Delaware District Court
Browse related patent infringement actions in the EDA and semiconductor verification space litigated in the Delaware District Court.
What this case signals for the EDA and CDC verification IP landscape
A five-day lifespan and six patents asserted tells a nuanced story about Synopsys’s enforcement strategy and the competitive dynamics in clock domain crossing verification.
Synopsys holds a deep CDC patent portfolio — and is willing to use it
Filing six patents in a single complaint signals portfolio depth and enforcement intent. EDA vendors with overlapping CDC verification tools should audit their exposure against the six asserted patents before Synopsys identifies a more favourable moment to refile or assert in a different forum.
Five-day dismissals suggest pre-litigation negotiations — or tactical pivots
When a plaintiff dismisses before a defendant even enters counsel, it typically reflects either a rapidly reached commercial resolution or a strategic correction in case strategy. Either scenario is commercially relevant to Real Intent’s customers and partners evaluating product continuity and IP risk.
Synopsys v Real — key questions answered
Synopsys asserted six U.S. patents: US9529948B2, US8359560B2, US8650513B2, US9792394B2, US10289773B2, and US8607173B2. All relate to electronic design automation technology, specifically clock domain crossing verification. The accused product was Real Intent’s Least Meridian CDC tool.
The public record does not disclose the reason for the rapid dismissal. Under Rule 41(a)(1)(A)(i), Synopsys was entitled to dismiss without court approval before Real Intent filed an answer. The five-day timeline suggests either a pre-litigation settlement, a licensing arrangement reached out of court, or a strategic decision to refile on different terms — but none of these is confirmed by the docket.
No. A dismissal without prejudice means Synopsys retains the right to refile the same claims in any competent court, subject to applicable statutes of limitations. No covenant not to sue and no declaratory judgment of non-infringement was recorded on the public docket. Real Intent’s Least Meridian CDC product remains potentially exposed to reassertion of all six patents.
Clock domain crossing (CDC) verification is an EDA methodology used to ensure reliable signal transfer between different clock domains in integrated circuit design, preventing metastability failures. It is a technically complex and commercially valuable capability, and Synopsys has built a substantial patent portfolio around its methods and tools. Competitors offering overlapping CDC verification functionality — like Real Intent’s Least Meridian CDC — are natural enforcement targets.
Yes. Real Intent — or any other party — could petition the Patent Trial and Appeal Board for inter partes review of any of the six asserted patents, provided the one-year window from service of a complaint has not expired and the petition meets the threshold for institution. Given the case was dismissed before Real Intent entered counsel, the IPR clock implications are nuanced and Real Intent should seek specific patent counsel advice on timing.
PatSnap Eureka searches patents and litigation data to answer instantly.